1
|
Loughran HM, Schirripa KM, Roecker AJ, Breslin MJ, Tong L, Fillgrove KL, Kuo Y, Bleasby K, Collier H, Altman MD, Ford MC, Newman JA, Drolet RE, Cosden M, Jinn S, Flick RB, Liu X, Minnick C, Watt ML, Lemaire W, Burlein C, Adam GC, Austin LA, Marcus JN, Smith SM, Fraley ME. Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections. ACS Med Chem Lett 2024; 15:123-131. [PMID: 38229758 PMCID: PMC10788949 DOI: 10.1021/acsmedchemlett.3c00436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 12/12/2023] [Accepted: 12/14/2023] [Indexed: 01/18/2024] Open
Abstract
Inhibition of glucosylceramide synthase (GCS) has been proposed as a therapeutic strategy for the treatment of Parkinson's Disease (PD), particularly in patients where glycosphingolipid accumulation and lysosomal impairment are thought to be contributing to disease progression. Herein, we report the late-stage optimization of an orally bioavailable and CNS penetrant isoindolinone class of GCS inhibitors. Starting from advanced lead 1, we describe efforts to identify an improved compound with a lower human dose projection, minimal P-glycoprotein (P-gp) efflux, and acceptable pregnane X receptor (PXR) profile through fluorine substitution. Our strategy involved the use of predicted volume ligand efficiency to advance compounds with greater potential for low human doses down our screening funnel. We also applied minimized electrostatic potentials (Vmin) calculations for hydrogen bond acceptor sites to rationalize P-gp SAR. Together, our strategies enabled the alignment of a lower human dose with reduced P-gp efflux, and favorable PXR selectivity for the discovery of compound 12.
Collapse
Affiliation(s)
| | | | | | | | - Ling Tong
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | | | - Yuhsin Kuo
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Kelly Bleasby
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Hannah Collier
- Merck
& Co., Inc., Rahway, New Jersey 07065, United States
| | | | - Melissa C. Ford
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | | | - Robert E. Drolet
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Mali Cosden
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Sarah Jinn
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | | | - Xiaomei Liu
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | | | - Marla L. Watt
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Wei Lemaire
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | | | - Gregory C. Adam
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Lauren A. Austin
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Jacob N. Marcus
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Sean M. Smith
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| | - Mark E. Fraley
- Merck
& Co., Inc., West Point, Pennsylvania 19486, United States
| |
Collapse
|
2
|
Roecker AJ, Schirripa KM, Loughran HM, Tong L, Liang T, Fillgrove KL, Kuo Y, Bleasby K, Collier H, Altman MD, Ford MC, Drolet RE, Cosden M, Jinn S, Hatcher NG, Yao L, Kandebo M, Vardigan JD, Flick RB, Liu X, Minnick C, Price LA, Watt ML, Lemaire W, Burlein C, Adam GC, Austin LA, Marcus JN, Smith SM, Fraley ME. Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease. ACS Med Chem Lett 2023; 14:146-155. [PMID: 36793422 PMCID: PMC9923837 DOI: 10.1021/acsmedchemlett.2c00441] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 01/04/2023] [Indexed: 01/13/2023] Open
Abstract
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in GBA, the gene that encodes for the lysosomal enzyme glucosylcerebrosidase, are a major genetic risk factor for the development of Parkinson's disease potentially through the accumulation of glucosylceramide and glucosylsphingosine in the CNS. A therapeutic strategy to reduce glycosphingolipid accumulation in the CNS would entail inhibition of the enzyme responsible for their synthesis, glucosylceramide synthase (GCS). Herein, we report the optimization of a bicyclic pyrazole amide GCS inhibitor discovered through HTS to low dose, oral, CNS penetrant, bicyclic pyrazole urea GCSi's with in vivo activity in mouse models and ex vivo activity in iPSC neuronal models of synucleinopathy and lysosomal dysfunction. This was accomplished through the judicious use of parallel medicinal chemistry, direct-to-biology screening, physics-based rationalization of transporter profiles, pharmacophore modeling, and use a novel metric: volume ligand efficiency.
Collapse
Affiliation(s)
- Anthony J. Roecker
- Discovery
Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Kathy M. Schirripa
- Discovery
Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - H. Marie Loughran
- Discovery
Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Ling Tong
- Discovery
Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Tao Liang
- Discovery
Process Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Kerry L. Fillgrove
- ADME
& Discovery Toxicology, Merck &
Co., Inc., West Point, Pennsylvania 19486, United States
| | - Yuhsin Kuo
- ADME
& Discovery Toxicology, Merck &
Co., Inc., West Point, Pennsylvania 19486, United States
| | - Kelly Bleasby
- ADME
Transporters, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Hannah Collier
- ADME
Transporters, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael D. Altman
- Computational
and Structural Chemistry, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Melissa C. Ford
- Computational
and Structural Chemistry, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Robert E. Drolet
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Mali Cosden
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Sarah Jinn
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Nathan G. Hatcher
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Lihang Yao
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Monika Kandebo
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Joshua D. Vardigan
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Rosemarie B. Flick
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Xiaomei Liu
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Christina Minnick
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Laura A. Price
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Marla L. Watt
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Wei Lemaire
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Christine Burlein
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Gregory C. Adam
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Lauren A. Austin
- Discovery
Pharmaceutical Sciences, Merck & Co.,
Inc., West Point, Pennsylvania 19486, United States
| | - Jacob N. Marcus
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Sean M. Smith
- Discovery
Biology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Mark E. Fraley
- Discovery
Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| |
Collapse
|
3
|
Polinski NK, Martinez TN, Ramboz S, Sasner M, Herberth M, Switzer R, Ahmad SO, Pelligrino LJ, Clark SW, Marcus JN, Smith SM, Dave KD, Frasier MA. The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models. Dis Model Mech 2022; 15:275065. [PMID: 35419585 PMCID: PMC9150115 DOI: 10.1242/dmm.049192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 04/11/2022] [Indexed: 11/28/2022] Open
Abstract
Heterozygous mutations in the GBA1 gene – encoding lysosomal glucocerebrosidase (GCase) – are the most common genetic risk factors for Parkinson's disease (PD). Experimental evidence suggests a correlation between decreased GCase activity and accumulation of alpha-synuclein (aSyn). To enable a better understanding of the relationship between aSyn and GCase activity, we developed and characterized two mouse models that investigate aSyn pathology in the context of reduced GCase activity. The first model used constitutive overexpression of wild-type human aSyn in the context of the homozygous GCase activity-reducing D409V mutant form of GBA1. Although increased aSyn pathology and grip strength reductions were observed in this model, the nigrostriatal system remained largely intact. The second model involved injection of aSyn preformed fibrils (PFFs) into the striatum of the homozygous GBA1 D409V knock-in mouse model. The GBA1 D409V mutation did not exacerbate the pathology induced by aSyn PFF injection. This study sheds light on the relationship between aSyn and GCase in mouse models, highlighting the impact of model design on the ability to model a relationship between these proteins in PD-related pathology. Summary: Phenotyping data for two novel mouse models combining glucocerebrosidase (GCase) deficiencies and alpha-synuclein pathology reveal the extent to which alpha-synuclein pathology is exacerbated by GCase deficiency.
Collapse
Affiliation(s)
- Nicole K Polinski
- The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station PO Box 4777, New York, NY 10163, USA
| | - Terina N Martinez
- The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station PO Box 4777, New York, NY 10163, USA
| | - Sylvie Ramboz
- PsychoGenics, Inc, 215 College Road, Paramus, NJ 07652, USA
| | - Michael Sasner
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA
| | - Mark Herberth
- Charles River Laboratories, 1407 George Road, Ashland, OH 44805, USA
| | - Robert Switzer
- NeuroScience Associates, 10915 Lake Ridge Drive, Knoxville, TN 37934, USA
| | - Syed O Ahmad
- Saint Louis University, 3437 Caroline Street, St. Louis, MO 63104, USA
| | | | - Sean W Clark
- Amicus Therapeutics, 1 Cedarbrook Dr, Cranbury, NJ 08512, USA
| | - Jacob N Marcus
- Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Sean M Smith
- Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Kuldip D Dave
- The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station PO Box 4777, New York, NY 10163, USA
| | - Mark A Frasier
- The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station PO Box 4777, New York, NY 10163, USA
| |
Collapse
|
4
|
Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, Hatcher NG, Ma L, Lemaire W, Adam GC, Burlein C, Minnick C, Flick R, Watt ML, Mulhearn J, Fraley M, Drolet RE, Marcus JN, Smith SM. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 2021; 159:105507. [PMID: 34509608 DOI: 10.1016/j.nbd.2021.105507] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 08/26/2021] [Accepted: 09/07/2021] [Indexed: 11/16/2022] Open
Abstract
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Mutations in GBA1 reduce enzyme activity and the resulting accumulation of glycosphingolipids may contribute to the underlying pathology of PD, possibly via altering lysosomal function. While reduction of GCase activity exacerbates α-synuclein (α-syn) aggregation, it has not been determined that this effect is the result of altered glycosphingolipid levels and lysosome function or some other effect of altering GCase. The glycosphingolipid GlcCer is synthesized by a single enzyme, glucosylceramide synthase (GCS), and small molecule inhibitors (GCSi) reduce cellular glycosphingolipid levels. In the present studies, we utilize a preformed fibril (PFF) rodent primary neuron in vitro model of α-syn pathology to investigate the relationship between glycosphingolipid levels, α-syn pathology, and lysosomal function. In primary cultures, pharmacological inhibition of GCase and D409V GBA1 mutation enhanced accumulation of glycosphingolipids and insoluble phosphorylated α-syn. Administration of a novel small molecule GCSi, benzoxazole 1 (BZ1), significantly decreased glycosphingolipid concentrations in rodent primary neurons and reduced α-syn pathology. BZ1 rescued lysosomal deficits associated with the D409V GBA1 mutation and α-syn PFF administration, and attenuated α-syn induced neurodegeneration of dopamine neurons. In vivo studies revealed BZ1 had pharmacological activity and reduced glycosphingolipids in the mouse brain to a similar extent observed in neuronal cultures. These data support the hypothesis that reduction of glycosphingolipids through GCS inhibition may impact progression of synucleinopathy and BZ1 is useful tool to further examine this important biology.
Collapse
Affiliation(s)
- Mali Cosden
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Sarah Jinn
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Lihang Yao
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Cheryl A Gretzula
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Monika Kandebo
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Dawn Toolan
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Nathan G Hatcher
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Lei Ma
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Wei Lemaire
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Gregory C Adam
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Christine Burlein
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Christina Minnick
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Rose Flick
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Marla L Watt
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - James Mulhearn
- Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, United States
| | - Mark Fraley
- Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, United States
| | - Robert E Drolet
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Jacob N Marcus
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Sean M Smith
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States.
| |
Collapse
|
5
|
Gentzel RC, Toolan D, Jinn S, Schachter JB, Ma L, Kahle PJ, Smith SM, Marcus JN. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction. Neurobiol Aging 2021; 106:12-25. [PMID: 34225000 DOI: 10.1016/j.neurobiolaging.2021.05.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 05/12/2021] [Accepted: 05/23/2021] [Indexed: 12/19/2022]
Abstract
Synucleinopathies are neurodegenerative disorders involving pathological alpha-synuclein (αSyn) protein, including dementia with Lewy bodies, multiple system atrophy and Parkinson's disease (PD). Current in vivo models of synucleinopathy include transgenic mice overexpressing αSyn variants and methods based on administration of aggregated, exogenous αSyn. Combining these techniques offers the ability to study consequences of introducing pathological αSyn into primed neuronal environments likely to develop synucleinopathy. Herein, we characterize the impacts pre-formed fibrils (PFFs) of recombinant, human αSyn have in mice overexpressing human A30P αSyn, a mutation associated with autosomal dominant PD. A30P mouse brain contains detergent insoluble αSyn biochemically similar to PD brain, and these mice develop Lewy-like synucleinopathy with age. Administration of PFFs in A30P mice resulted in regionally-specific accumulations of phosphorylated synuclein, microglial induction and a motor phenotype that differed from PFF-induced effects in wildtype mice. Surprisingly, PFF-induced losses of tyrosine hydroxylase were similar in A30P and wildtype mice. Thus, the PFF-A30P model recapitulates key aspects of synucleinopathy with induction of microglia, creating an appropriate system for evaluating neurodegenerative therapeutics.
Collapse
Affiliation(s)
- Renee C Gentzel
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Dawn Toolan
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Sarah Jinn
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Joel B Schachter
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA; Currently at Takeda Pharmaceutics, Inc., San Diego, CA, USA
| | - Lei Ma
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Philipp J Kahle
- Laboratory of Functional Neurogenetics, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and, German Center for Neurodegenerative Diseases, University of Tübingen, Germany
| | - Sean M Smith
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Jacob N Marcus
- Neuroscience Discovery, Merck & Co., Inc., Kenilworth, NJ, USA.
| |
Collapse
|
6
|
Marcus JN, Tanis K, Pearson M, Wang X, Smith S, Howell B, Gustafson E, Winrow CJ. P2‐010: Genome‐wide transcriptional profiles of Alzheimer's disease mouse models and comparison to human gene expression. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, Lutter M. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 2011; 222:289-94. [PMID: 21377495 DOI: 10.1016/j.bbr.2011.02.044] [Citation(s) in RCA: 97] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2011] [Revised: 02/22/2011] [Accepted: 02/28/2011] [Indexed: 12/31/2022]
Abstract
The orexin/hypocretin system has the potential to significantly modulate affect, based on both the neuroanatomical projection patterns of these neurons and on the sites of orexin receptor expression. However, there is little data supporting the role of specific orexin receptors in the modulation of depression-like behavior. Here we report behavioral profiling of mice after genetic or pharmacologic inhibition of hcrtr1 and 2 receptor signaling. Hcrtr1 null mice displayed a significant reduction in behavioral despair in the forced swim test and tail suspension test. Wild-type mice treated with the hcrtr1 antagonist SB-334867 also displayed a similar reduction in behavioral despair. No difference in anxiety-like behavior was noted following hcrtr1 deletion. In contrast, hcrtr2-null mice displayed an increase in behavioral despair with no effect on measures of anxiety. These studies suggest that the balance of orexin action at either the hcrtr1 or the hcrtr2 receptor produces an anti-depressant or pro-depressant like effect, depending on the receptor subtype activated.
Collapse
Affiliation(s)
- Michael M Scott
- Department of Internal Medicine, Division of Hypothalamic Research, West Point, PA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dillon GM, Shelton D, McKinney AP, Caniga M, Marcus JN, Ferguson MT, Kornecook TJ, Dodart JC. Prefrontal cortex lesions and scopolamine impair attention performance of C57BL/6 mice in a novel 2-choice visual discrimination task. Behav Brain Res 2009; 204:67-76. [PMID: 19416740 DOI: 10.1016/j.bbr.2009.04.036] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2009] [Revised: 04/22/2009] [Accepted: 04/27/2009] [Indexed: 11/18/2022]
Abstract
Sustained attention is defined as the ability or capacity to remain focused on the occurrence of rare events over long periods of time. We describe here the development of a novel, operant-based attention task that can be learned by mice in 8-10 days. Mice were trained on a 2-choice visual discrimination task in an operant chamber, wherein the correct response on any given trial was a lever-press cued by a stimulus light. Upon reaching a criterion of greater than 80% correct responses, all subjects were tested in a mixed-trial attention paradigm combining four different stimulus durations within a single session (0.5, 1, 2, or 10 s). During attention testing, the percentage of correct responses decreased as a function of stimulus duration, indicating a performance decrement which parallels increasing attentional demand within the task. Pretreatment with the muscarinic-receptor antagonist scopolamine yielded a reliable, dose-dependent performance deficit whereas nicotine treatment improved the percentage of correct responses during trials with the greatest attentional demand. Moreover, medial prefrontal cortex lesions impaired attention performance without affecting acquisition or retention of the discrimination rule. These results underscore the utility of this task as a novel means of assessing attentional processes in mice in a relatively high-throughput manner.
Collapse
Affiliation(s)
- Gregory M Dillon
- Merck Research Laboratories, CNS Pharmacology, 33 Avenue Louis Pasteur, Boston, MA 02115, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Dillon GM, Qu X, Marcus JN, Dodart JC. Excitotoxic lesions restricted to the dorsal CA1 field of the hippocampus impair spatial memory and extinction learning in C57BL/6 mice. Neurobiol Learn Mem 2008; 90:426-33. [DOI: 10.1016/j.nlm.2008.05.008] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2008] [Revised: 05/12/2008] [Accepted: 05/17/2008] [Indexed: 10/21/2022]
|
10
|
Crispino JL, Marcus JN, Hering H. P3‐401: Validation of a TRPM3‐specific antibody and TRMP3 expression in mouse brain. Alzheimers Dement 2008. [DOI: 10.1016/j.jalz.2008.05.1972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Abstract
Relatively little is known about the mechanisms that link changing levels of glucose and neuronal activity. A paper in the current issue of Neuron by Burdakov et al. demonstrates that orexin/hypocretin neurons are inhibited by rising glucose in part due to membrane potential effects mediated by tandem-pore K(+) (K(2P)) channels. The findings may shed light on the mechanisms that link hypoglycemia and coordinated arousal and autonomic responses.
Collapse
Affiliation(s)
- Michael M Scott
- Center for Hypothalamic Research, University of Texas Southwestern Medical Center, Dallas, 75390, USA
| | | | | |
Collapse
|
12
|
Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2006; 115:3564-72. [PMID: 16322794 PMCID: PMC1297251 DOI: 10.1172/jci26002] [Citation(s) in RCA: 458] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2005] [Accepted: 10/04/2005] [Indexed: 12/18/2022] Open
Abstract
Ghrelin is the endogenous ligand for the growth hormone secretagogue receptor (GHSR; ghrelin receptor). Since its discovery, accumulating evidence has suggested that ghrelin may play a role in signaling and reversing states of energy insufficiency. For example, ghrelin levels rise following food deprivation, and ghrelin administration stimulates feeding and increases body weight and adiposity. However, recent loss-of-function studies have raised questions regarding the physiological significance of ghrelin in regulating these processes. Here, we present results of a study using a novel GHSR-null mouse model, in which ghrelin administration fails to acutely stimulate food intake or activate arcuate nucleus neurons. We show that when fed a high-fat diet, both female and male GHSR-null mice eat less food, store less of their consumed calories, preferentially utilize fat as an energy substrate, and accumulate less body weight and adiposity than control mice. Similar effects on body weight and adiposity were also observed in female, but not male, GHSR-null mice fed standard chow. GHSR deletion also affected locomotor activity and levels of glycemia. These findings support the hypothesis that ghrelin-responsive pathways are an important component of coordinated body weight control. Moreover, our data suggest that ghrelin signaling is required for development of the full phenotype of diet-induced obesity.
Collapse
MESH Headings
- Adipose Tissue/metabolism
- Alleles
- Analysis of Variance
- Animal Feed
- Animals
- Blood Glucose/metabolism
- Blotting, Southern
- Blotting, Western
- Body Composition
- Body Weight
- Crosses, Genetic
- DNA/metabolism
- Diet
- Female
- Gene Deletion
- Genetic Predisposition to Disease
- Genotype
- Ghrelin
- Heterozygote
- Homeostasis
- Hyperglycemia/metabolism
- Insulin-Like Growth Factor I/metabolism
- Leptin/metabolism
- Magnetic Resonance Spectroscopy
- Male
- Mice
- Mice, Inbred C57BL
- Models, Genetic
- Neurons/metabolism
- Obesity/genetics
- Obesity/metabolism
- Peptide Hormones/chemistry
- Peptide Hormones/physiology
- Phenotype
- RNA, Messenger/metabolism
- Receptors, G-Protein-Coupled/genetics
- Receptors, G-Protein-Coupled/physiology
- Receptors, Ghrelin
- Recombinant Proteins/genetics
- Recombinant Proteins/metabolism
- Recombination, Genetic
- Signal Transduction
- Silver Staining
- Time Factors
Collapse
Affiliation(s)
- Jeffrey M Zigman
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Orexin increases blood pressure and orexin-immunoreactive (IR) axons robustly innervate the spinal cord. Seeking anatomical evidence for direct effects of orexin on sympathetic preganglionic neurons (SPN), we used immunohistochemistry to study the relationships between orexin-IR axons and SPN identified by immunoreactivity for choline acetyltransferase (ChAT) or for cholera toxin B retrogradely transported from the superior cervical ganglion (SCG). In the intermediolateral cell column (IML), varicose, orexin-positive axons closely apposed almost all SPN in segments T1 and T2, but appositions were rare in T4-L2. Orexin fibers also apposed ChAT-IR cell bodies in the intercalated nucleus and the central autonomic area from T1 to L2. Orexin-IR synapses were identified ultrastructurally on SPN projecting to the SCG. Since SPN involved in cardiovascular control cluster in the IML of mid- and lower thoracic cord, these findings suggest that orexin affects blood pressure by acting on supraspinal neurons rather than SPN.
Collapse
Affiliation(s)
- I J Llewellyn-Smith
- Cardiovascular Neuroscience Group, Cardiovascular Medicine and Centre for Neuroscience, Flinders University, Bedford Park, SA 5042, Australia.
| | | | | | | | | | | |
Collapse
|
14
|
Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38:715-30. [PMID: 12797957 DOI: 10.1016/s0896-6273(03)00330-1] [Citation(s) in RCA: 450] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Narcolepsy-cataplexy, a neurological disorder associated with the absence of hypothalamic orexin (hypocretin) neuropeptides, consists of two underlying problems: inability to maintain wakefulness and intrusion of rapid eye movement (REM) sleep into wakefulness. Here we document, using behavioral, electrophysiological, and pharmacological criteria, two distinct classes of behavioral arrests exhibited by mice deficient in orexin-mediated signaling. Both OX2R(-/-) and orexin(-/-) mice are similarly affected with behaviorally abnormal attacks of non-REM sleep ("sleep attacks") and show similar degrees of disrupted wakefulness. In contrast, OX2R(-/-) mice are only mildly affected with cataplexy-like attacks of REM sleep, whereas orexin(-/-) mice are severely affected. Absence of OX2Rs eliminates orexin-evoked excitation of histaminergic neurons in the hypothalamus, which gate non-REM sleep onset. While normal regulation of wake/non-REM sleep transitions depends critically upon OX2R activation, the profound dysregulation of REM sleep control unique to the narcolepsy-cataplexy syndrome emerges from loss of signaling through both OX2R-dependent and OX2R-independent pathways.
Collapse
Affiliation(s)
- Jon T Willie
- Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297:609-11. [PMID: 12142539 DOI: 10.1126/science.1072327] [Citation(s) in RCA: 338] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
D-fenfluramine (d-FEN) was once widely prescribed and was among the most effective weight loss drugs, but was withdrawn from clinical use because of reports of cardiac complications in a subset of patients. Discerning the neurobiology underlying the anorexic action of d-FEN may facilitate the development of new drugs to prevent and treat obesity. Through a combination of functional neuroanatomy, feeding, and electrophysiology studies in rodents, we show that d-FEN-induced anorexia requires activation of central nervous system melanocortin pathways. These results provide a mechanistic explanation of d-FEN's anorexic actions and indicate that drugs targeting these downstream melanocortin pathways may prove to be effective and more selective anti-obesity treatments.
Collapse
MESH Headings
- Animals
- Appetite Depressants/pharmacology
- Arcuate Nucleus of Hypothalamus/drug effects
- Arcuate Nucleus of Hypothalamus/metabolism
- Feeding Behavior/drug effects
- Fenfluramine/pharmacology
- Male
- Melanocyte-Stimulating Hormones/pharmacology
- Mice
- Mice, Obese
- Mice, Transgenic
- Neurons/drug effects
- Neurons/metabolism
- Paraventricular Hypothalamic Nucleus/drug effects
- Paraventricular Hypothalamic Nucleus/metabolism
- Patch-Clamp Techniques
- Pro-Opiomelanocortin/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptor, Melanocortin, Type 3
- Receptor, Melanocortin, Type 4
- Receptor, Serotonin, 5-HT2C
- Receptors, Corticotropin/metabolism
- Receptors, Serotonin/metabolism
- Serotonin/metabolism
- Serotonin Agents/pharmacology
- alpha-MSH/metabolism
Collapse
Affiliation(s)
- Lora K Heisler
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110:43-52. [PMID: 12093887 PMCID: PMC151031 DOI: 10.1172/jci15595] [Citation(s) in RCA: 179] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Glucagon-like peptide-1 (GLP-1) released from the gut functions as an incretin that stimulates insulin secretion. GLP-1 is also a brain neuropeptide that controls feeding and drinking behavior and gastric emptying and elicits neuroendocrine responses including development of conditioned taste aversion. Although GLP-1 receptor (GLP-1R) agonists are under development for the treatment of diabetes, GLP-1 administration may increase blood pressure and heart rate in vivo. We report here that centrally and peripherally administered GLP-1R agonists dose-dependently increased blood pressure and heart rate. GLP-1R activation induced c-fos expression in the adrenal medulla and neurons in autonomic control sites in the rat brain, including medullary catecholamine neurons providing input to sympathetic preganglionic neurons. Furthermore, GLP-1R agonists rapidly activated tyrosine hydroxylase transcription in brainstem catecholamine neurons. These findings suggest that the central GLP-1 system represents a regulator of sympathetic outflow leading to downstream activation of cardiovascular responses in vivo.
Collapse
Affiliation(s)
- Hiroshi Yamamoto
- Department of Medicine and Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002. [DOI: 10.1172/jci0215595] [Citation(s) in RCA: 370] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
19
|
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435:6-25. [PMID: 11370008 DOI: 10.1002/cne.1190] [Citation(s) in RCA: 1194] [Impact Index Per Article: 51.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Orexins (hypocretins) are neuropeptides synthesized in the central nervous system exclusively by neurons of the lateral hypothalamus. Orexin-containing neurons have widespread projections and have been implicated in complex physiological functions including feeding behavior, sleep states, neuroendocrine function, and autonomic control. Two orexin receptors (OX(1)R and OX(2)R) have been identified, with distinct expression patterns throughout the brain, but a systematic examination of orexin receptor expression in the brain has not appeared. We used in situ hybridization histochemistry to examine the patterns of expression of mRNA for both orexin receptors throughout the brain. OX(1)R mRNA was observed in many brain regions including the prefrontal and infralimbic cortex, hippocampus, paraventricular thalamic nucleus, ventromedial hypothalamic nucleus, dorsal raphe nucleus, and locus coeruleus. OX(2)R mRNA was prominent in a complementary distribution including the cerebral cortex, septal nuclei, hippocampus, medial thalamic groups, raphe nuclei, and many hypothalamic nuclei including the tuberomammillary nucleus, dorsomedial nucleus, paraventricular nucleus, and ventral premammillary nucleus. The differential distribution of orexin receptors is consistent with the proposed multifaceted roles of orexin in regulating homeostasis and may explain the unique role of the OX(2)R receptor in regulating sleep state stability.
Collapse
Affiliation(s)
- J N Marcus
- Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The circadian dynamics of responses to cyclic guanosine 3',5'-monophosphate (cGMP) in in vitro experiments and the stimulating effects of the pineal hormone melatonin on cGMP levels both in vitro and in vivo provoked an investigation into the diurnal pattern of occurrence of this second messenger in human plasma and its correlation with plasma melatonin levels. Plasma cGMP levels were measured in 9 normal human subjects who were over 50 years of age. Samples were obtained hourly through a 20-h period (11 a.m. to 7 a.m.) that included the subjects' habitual hours of nocturnal sleep; physical activity was kept to a minimum during the daylight hours. The area under the time-plasma cGMP concentration curve showed a significant increase during the period of nocturnal sleep compared to that observed during the period of daytime wakefulness. The individual temporal pattern of the nocturnal rise in plasma cGMP differed among the subjects; however, the initial increase typically was observed soon after bedtime. No significant correlation was observed between individual nocturnal plasma melatonin levels and cGMP levels.
Collapse
Affiliation(s)
- I V Zhdanova
- Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge 02139, USA
| | | | | | | | | | | |
Collapse
|
21
|
Affiliation(s)
- P Watson
- Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE 68178, USA
| | | | | |
Collapse
|
22
|
Affiliation(s)
- J N Marcus
- Department of Pathology, St. Luke's Hospital, Chesterfield, MO 63017, USA.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Complete hydatiform moles (CHM) may be are diploid or tetraploid. The proportions vary in the literature. To date, there has not been a systematic characterization of these two types. This study is a retrospective investigation of clinicopathologic differences between diploid and tetraploid CHMs. Thirteen formalin-fixed, paraffin-embedded CHMs were analyzed for DNA content by flow cytometry (FC). Using standard flow cytometric definitions, histograms were classified as FC-diploid or FC-tetraploid (4N peak > or = 15% of 2N peak and cell cycle events to 8N) and compared with respect to selected clinical and pathologic features. Eight CHMs (61%) met the criteria of tetraploidy by flow cytometry, although all five FC-diploid cases harbored minor (< 15%) tetraploid subpopulations. Patients with tetraploid moles were older (mean age 32.8 years vs. 19.6 years, p < 0.005), presented at lower preevacuation gestational ages (12.7 weeks vs. 15.4 weeks, p < 0.05), had higher mean serum beta-HCG levels (2.82 x 10(5) i.u. vs. 0.99 x 10(5) i.u., p = 0.07), and higher DNA S-phase fractions (17.9% vs. 7.0%, p = 0.002). No significant differences were found in other histological features. No moles recurred. In this small sample of CHMs, tetraploidy was common. Compared with the FC-diploid CHMs, FC-tetraploid CHMs occurred in older patients with lower gestational age, higher serum beta-HCG levels, and higher DNA S-phase fraction by flow cytometry.
Collapse
Affiliation(s)
- C Bewtra
- Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska, USA
| | | | | |
Collapse
|
24
|
Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77:697-709. [PMID: 8616762 DOI: 10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w] [Citation(s) in RCA: 366] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND The purpose of this investigation was to determine if there are pathobiologic differences between BRCA1-related and BRCA2-related hereditary breast cancer (HBC) and non-HBC. METHODS On the basis of linkage to chromosomes 17q or 13q and/or the presence of ovarian and male breast cancer, HBC families were classified as either "BRCA1-related" (26 families, 90 breast cancer pathology cases) or "Other" (26 families, 85 cases), in which most BRCA2 cases were likely to reside. Cases were compared with 187 predominantly non-HBC cases. Tumors were assessed for histologic type, grade, and ploidy and S-phase fraction by quantitative DNA flow cytometry. Clinical presentation and available follow-up data were obtained. RESULTS BRCA1-related and Other HBC patients each presented at lower stage (P = 0.003) and earlier age than non-HBC patients (mean, 42.8 years and 47.1 years vs. 62.9 years, P = 0.0001). Compared with non-HBC, invasive BRCA1-related HBC had a lower diploidy rate (13% vs. 35%; P = 0.002), lower mean aneuploid DNA index (1.53 vs. 1.73; P= 0.002), and strikingly higher proliferation rates (mitotic grade 3; odds ratio [OR]= 4.42; P= 0.001; aneuploid mean S-phase fraction 16.5% vs. 9.3%, P < 0.0001). Other HBC patients, including patients in two BRCA2- linked families, had more tubular-lobular group (TLG) carcinomas (OR = 2.56, P = 0.007). All trends were independent of age. A nonsignificant trend toward better crude survival in both HBC groups was age- and stage-dependent. Compared with Other HBC, BRCA1-related HBC patients had fewer recurrences (P = 0.013), a trend toward lower specific death rates, and fared no worse than breast cancer patients at large. Other HBC patients, despite neutral prognostic indicators, fared worse. CONCLUSIONS BRCA1-related HBCs are more frequently aneuploid and have higher tumor cell proliferation rates compared with Other HBC. Despite these adverse prognostic features, BRCA1-related HBC patients have paradoxically lower recurrence rates than Other HBC patients. The excess of TLG cancers in the "Other" HBC group may be associated with BRCA2 linkage.
Collapse
Affiliation(s)
- J N Marcus
- Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- H T Lynch
- Department of Preventive Medicine Creighton University School of Medicine, Omaha, Nebraska 68178, USA
| | | |
Collapse
|
26
|
Bacus SS, Zelnick CR, Chin DM, Yarden Y, Kaminsky DB, Bennington J, Wen D, Marcus JN, Page DL. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. Am J Pathol 1994; 145:1337-48. [PMID: 7992839 PMCID: PMC1887499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The histological hallmarks for the diagnosis of medullary breast cancer are circumscription, syncytial architecture, diffuse inflammatory infiltrate, and highly atypical nuclei. The biological and prognostic implication is a lower propensity to metastasize. We studied 19 medullary carcinomas for expression of the intercellular adhesion molecule-1 and lymphocyte-function-associated antigen-1, Neu differentiation factor, tumor necrosis factor-alpha, and the expression of HER-2/neu, HER-4, and HER-3 receptors. Our study revealed that all of the 19 medullary carcinomas expressed the intercellular adhesion molecule-1 and lymphocyte function associated antigen. Eighteen of 19 cancers expressed Neu differentiation factor and tumor necrosis factor-alpha. All medullary cancers expressed the HER-2/neu receptor, however, in the majority of the cases, the staining was confined to the cytoplasm. Only 4 of 12 cancers expressed HER-4 and none of the eight medullary cancers tested expressed HER-3. By comparison, in a control group of infiltrating ductal carcinomas, expression of intercellular adhesion molecule-1, lymphocyte function associated antigen-1, and Neu differentiation factor was positive in about 25 to 30% of the cases, HER-4 was expressed in 75% and HER-3 in 95% of the cases. Taken together, our observations suggest that the expression of intercellular adhesion molecule-1, lymphocyte function associated antigen, Neu differentiation factor, and tumor necrosis factor-alpha as factors that may affect the special morphology and the biological behavior that characterizes medullary carcinomas.
Collapse
Affiliation(s)
- S S Bacus
- Advanced Cellular Diagnostics, Elmhurst, Illinois 60126
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Ali AA, Marcus JN, Harvey JP, Roll R, Hodgson CP, Wildrick DM, Chakraborty A, Boman BM. RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines. FASEB J 1993; 7:931-7. [PMID: 8344490 DOI: 10.1096/fasebj.7.10.8344490] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The pattern of human retinoblastoma (RB1) gene protein expression was directly examined in normal and malignant human colorectal tissues and in seven colorectal carcinoma cell lines by immunohistochemistry using the mouse monoclonal antibody (RB-MAb-1) directed against the retinoblastoma protein (RB). This is the first demonstration of RB immunostaining in adult human colonic epithelium and colorectal carcinomas. Specificity using RB-MAb-1 was confirmed by western blot analysis, which showed bands of 110-116 kDa corresponding to the sizes of unphosphorylated and phosphorylated RB. RB staining of normal adult colonic epithelium was confined to the nucleus and was most intense in the transitional zone of the crypt, whereas lumenal cells (fully differentiated) were RB negative. Primary colorectal carcinomas and all the colon cancer cell lines stained positively for nuclear RB, but the expression was heterogeneous with varying fractions of RB negative cells present. Because we and others have previously shown that loss or inactivation of the RB1 gene is infrequent in colorectal carcinomas, reduced RB expression in such cells is probably due to a cellular regulatory mechanism. For example, RB negative cells may be those in early-G1 phase (known to have reduced RB levels) or growth-arrested cells that have differentiated. The ability to directly detect RB in primary colorectal carcinomas will permit assessment of whether heterogeneous expression of the RB1 gene product has prognostic significance for survival of patients with this cancer.
Collapse
Affiliation(s)
- A A Ali
- Creighton Cancer Center, Creighton University School of Medicine, Omaha, Nebraska 68178
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84:845-55. [PMID: 1317462 DOI: 10.1093/jnci/84.11.845] [Citation(s) in RCA: 510] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation. PURPOSE This study was designed to determine whether p53 protein accumulation in breast cancers correlates with p53 gene mutation, with survival, and with five pathobiologic factors associated with prognosis. METHODS IgG1 monoclonal antibody to human p53 protein (PAb 1801) and immunohistochemical methods were used to detect p53 protein accumulation in archival formalin-fixed, paraffin-embedded, randomly selected carcinomas. We studied 295 invasive ductal carcinomas from the Massachusetts General Hospital; 151 were determined to be sporadic (not hereditary). We also studied 97 invasive ductal carcinomas--21 sporadic and 76 familial (hereditary)--from Creighton University. In addition, we examined 31 archival in situ carcinomas, 15 snap-frozen invasive ductal carcinomas, primary cell cultures from three benign breast tissue samples, and breast carcinoma cell lines MDA-MB-231 and MDA-MB-468. RESULTS Nuclear p53 protein was observed in 16% of the 31 in situ carcinomas, 22% of the 172 sporadic carcinomas, 34% of the 50 tumors from patients with familial breast cancer, 52% of the 23 tumors from patients with the familial breast and ovarian cancer syndrome, and all three tumors from two patients with the Li-Fraumeni syndrome. There was complete concordance between p53 gene mutation and p53 protein accumulation in the 15 snap-frozen carcinomas and in both breast carcinoma cell lines. Statistically significant associations of p53 protein accumulation with estrogen receptor negativity and with high nuclear grade were found. There were statistically significant associations, independent of other prognostic factors, between p53 protein accumulation and metastasis-free and overall survival, for randomly accrued and for both sporadic and familial tumors. CONCLUSIONS Immunohistochemically detected p53 protein accumulation was an independent marker of shortened survival and was seen more often in familial than in sporadic carcinomas. Our findings also suggest a correlation between p53 protein accumulation and p53 gene mutation.
Collapse
Affiliation(s)
- A D Thor
- Department of Pathology, Massachusetts General Hospital, Boston 02114
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Host susceptibility factors have been documented in both HD and NHL wherein a subset of pedigrees provide evidence for an autosomal dominantly inherited factor. Families with both HD and NHL occurring in genetically informative patients provide evidence in support of a possible common pathogenetic pathway for these diseases, as does recent cytogenetic and molecular genetic evidence. AIDS as an unmasking factor for familial predisposition to lymphoma and other cancers may be a powerful tool for identifying lymphoma- and cancer-prone families, but to date has not been employed. In concert with ecogenetic research, it will be important that lymphoma-prone families be subjected to multidisciplined research involving experimental designs developed by geneticists and epidemiologists in concert with pathologists, immunologists, and molecular geneticists.
Collapse
Affiliation(s)
- H T Lynch
- Department of Preventive Medicine/Public Health, Creighton University School of Medicine, Omaha, Nebraska 68178
| | | | | |
Collapse
|
30
|
Lynch HT, Marcus JN, Weisenburger DD, Watson P, Fitzsimmons ML, Grierson H, Smith DM, Lynch J, Purtilo D. Genetic and immunopathological findings in a lymphoma family. Br J Cancer 1989; 59:622-6. [PMID: 2713249 PMCID: PMC2247145 DOI: 10.1038/bjc.1989.126] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We have studied a remarkable family with seven cases of malignant lymphoma extending through three generations wherein five sisters and their mother had histopathologically documented non-Hodgkin's lymphoma, while a granddaughter had Hodgkin's disease. An immunological study of three lymphoma survivors, nine of their first degree relatives, and four spouse controls was undertaken. Significant findings consisted of a depressed serum IgG3 level in four of the nine first-degree relatives; in two of these four, lymphocyte stimulation by both pokeweed mitogen and concanavalin A were significantly depressed. The subtle immunological abnormalities present in this kindred may be associated with the pathogenesis of the lymphomas.
Collapse
Affiliation(s)
- H T Lynch
- Department of Preventive Medicine/Public Health, Creighton University School of Medicine, Omaha, NE 68178
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Abstract
We describe new pathologic findings in a hereditary nonpolyposis colorectal cancer family. Affected family members developed multiple small adenomas with right-sided predominance; many adenomas had an unusual appearance featuring slightly elevated lesions with adenomatous changes confined to the upper regions of the colonic crypts. We have adopted the previously established term "flat adenoma" for these lesions. This phenotype may be a morphologic marker for at least one subset of hereditary nonpolyposis colorectal cancer.
Collapse
Affiliation(s)
- H T Lynch
- Department of Preventive Medicine/Public Health, Creighton University School of Medicine, Omaha, NE 68178
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
The first case of pure squamous cell carcinoma arising in a villous adenoma of the cecum is reported, and the literature of squamous cell carcinoma of the colon is reviewed. The possible origin of this neoplasm in adenomas of the colon, similar to that of adenocarcinoma, is discussed, and the site distributions of adenocarcinoma and squamous cell carcinoma are compared. The distribution of primary colonic squamous cell carcinoma is found to be predominantly right-sided in comparison to adenocarcinoma (p less than 0.05). Although this result does not preclude adenomas as the origin of most squamous cell carcinomas, it suggests the influence of as yet unknown site-asymmetric factors that are different from those for adenocarcinoma.
Collapse
Affiliation(s)
- D E Lundquest
- Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska 68131
| | | | | | | |
Collapse
|
34
|
DeMeester TR, Fuchs KH, Ball CS, Albertucci M, Smyrk TC, Marcus JN. Experimental and clinical results with proximal end-to-end duodenojejunostomy for pathologic duodenogastric reflux. Ann Surg 1987; 206:414-26. [PMID: 3662657 PMCID: PMC1493213 DOI: 10.1097/00000658-198710000-00003] [Citation(s) in RCA: 154] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Existing Roux-en-Y bile diversion procedures for duodenogastric reflux coupled with distal gastric resection or antrectomy and vagotomy have varied success due to interruption of the physiologic relationships between stomach and duodenum, the reduction of the gastric reservoir, the side effects of vagotomy, and the effect of the Roux limb on gastric emptying. A new bile diversion procedure, suprapapillary Roux-en-Y duodenojejunostomy, was studied, which eliminates the need for gastric resection to prevent jejunal ulcers by preserving duodenal inhibition of gastric acid secretion and the protective effects of duodenal secretion on the surrounding mucosa. Experimentally, the incidence of jejunal ulceration was significantly decreased by the preservation of the proximal duodenum. Clinically, bile diversion by suprapapillary Roux-en-Y duodenojejunostomy alleviates symptoms of duodenogastric reflux disease without being ulcerogenic (in the presence of normal gastric secretion) or prolonging gastric emptying.
Collapse
Affiliation(s)
- T R DeMeester
- Department of Surgery, Creighton University, School of Medicine, Omaha, NE 68131
| | | | | | | | | | | |
Collapse
|
35
|
Lynch HT, Fitzgibbons RJ, Lanspa SJ, Marcus JN, Lynch JF, Kopelovich L. Familial polyposis coli and neurofibromatosis in the same patient: a family study. Cancer Genet Cytogenet 1987; 28:245-51. [PMID: 3040223 DOI: 10.1016/0165-4608(87)90210-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
This report describes a family wherein two major genes--one for familial polyposis coli and the second for von Recklinghausen's neurofibromatosis--were segregating. A patient whose father had familial poliposis coli and whose mother had neurofibromatosis manifested both of these disorders.
Collapse
|
36
|
Fitzgibbons RJ, Lynch HT, Stanislav GV, Watson PA, Lanspa SJ, Marcus JN, Smyrk T, Kriegler MD, Lynch JF. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Ann Surg 1987; 206:289-95. [PMID: 3632093 PMCID: PMC1493182 DOI: 10.1097/00000658-198709000-00007] [Citation(s) in RCA: 160] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Primary genetic factors are etiologic in at least 5-10% of patients with colon cancer. The polyposis syndromes (FPC) are easily identified examples because of the spectacular number of polyps. The hereditary nonpolyposis syndromes (HNPCC), although five times more common than FPC, are usually not recognized because they do not have such a distinctive clinical, premonitory genetic marker. Colorectal cancer expression was surveyed in 10 extended, thoroughly documented HNPCC kindreds. One hundred sixteen patients were found to have 183 colorectal cancers. Despite the striking family history, less than 5% were correctly treated by subtotal colectomy. This provided a unique opportunity to study the natural history. Five findings differed significantly (p less than 0.05) from patients with sporadic colon cancer: (1) mean age of initial colon cancer diagnosed was 45.6 years; (2) 69.1% of first colon cancers were located proximal to the splenic flexure of the colon; (3) 18.1% had synchronous colon cancer; (4) 24.2% had metachronous colon cancer develop with life table analysis showing the risk for a metachronous lesion at 10 years to be 40%; and (5) only 23.3% of cancers were located in the sigmoid colon or rectum. Based on this data, it is recommended that the family history of all patients with a newly diagnosed colon cancer be evaluated for evidence of this syndrome. If an autosomal dominant inheritance pattern emerges, an in-depth genetic investigation is indicated. When HNPCC is confirmed, the following recommendations apply: a subtotal abdominal colectomy is indicated at the time of the initial colon cancer because of the risk of synchronous and metachronous lesions. The rectum should be spared in favor of careful lifetime surveillance because of the proclivity for proximal colon cancer involvement. As yet unaffected members of a newly diagnosed HNPCC kindred who are in the "direct genetic line" should be cautioned that they are at 50% risk and must begin an intensive surveillance program beginning in the third decade with careful attention to the right colon. Patients from newly diagnosed HNPCC families who have had a previous conventional colectomy for colon cancer should, at the very least, enter an intensive surveillance program; a prophylactic completion subtotal colectomy should be considered for patients who are less than totally compliant.
Collapse
|
37
|
Marcus JN. Gall granule sudanophilia? Am J Clin Pathol 1984; 81:275-6. [PMID: 6198904 DOI: 10.1093/ajcp/81.2.275a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
38
|
Abstract
Melanin production by a medullary thyroid carcinoma (MTC) is reported and discussed. Immunohistochemically, the tumor cells contained calcitonin; by electron microscopy, they bore numerous, heterogeneous granules similar to those described previously in MTCs. One small focus of tumor was pigmented. Here, melanosomes in different stages of maturation were found in dendritic cells that ramified among granule-bearing cells. The remarkable phenotypic divergence in this solitary, nongerm cell neoplasm is unusual but not so surprising in light of the APUD nature and neural crest origin of both the melanocyte and the thyroid C cell, which gives rise to MTC. The authors view the calcitonin and melanosome phenotypes as closely related tumor clones evolving from a common precursor neoplastic cell. This unique "experiment of nature" adds to the set of rare human tumors that make melanin "ectopically."
Collapse
|